Eisai Co. Ltd. and Sysmex Corp. made a joint announcement this week declaring that the two companies have agreed on a non-exclusive partnership to develop new diagnostics for the field of dementia.
The two companies agreed there needs to be new technologies in the diagnosing of Alzheimer’s and that these technologies need to be easier in execution, inexpensive and less invasive for the patients. As it stands, Alzheimer’s is usually diagnosed by tests that include brain imaging and cerebrospinal fluid examinations. Issues surrounding these types of tests revolve around the lack of facilities where these tests takes place, how expensive they are and the invasive nature of the tests. These matters are what Eisai and Sysmex are committed to solving with their agreement.
Sysmex specializes in clinical diagnostics and has developed innovative technological advancements that can detect genetic, protein and cellular biomarkers in samples of blood. Eisai has more than 30 years of knowledge and experience in the discovery and development of drugs related to the dementia field. Specifically, it has produced product information for Aricept, a treatment option for Alzheimer’s disease and dementia.